Literature DB >> 32145086

TRIM32 promotes inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes.

Tian Liang1, Min Song1, Kewu Xu2, Chenglong Guo2, Hongbin Xu2, Hongwei Zhang2, Lanping Xu3.   

Abstract

Rheumatoid arthritis (RA) is a worldwide autoimmune disease. The study of its aetiology and mechanism has always been a focus topic in medicine. This research was designed to investigate the effect of E3 ubiquitin ligase tripartite motif protein 32 (TRIM32) in rheumatoid arthritis (RA). We found in fibroblast-like synoviocytes (FLS) of RA patients, the expression of TRIM32 was significantly increased compared with its expression in osteoarthritis (OA) patients FLS. A widely used pro-inflammatory stimuli tumour necrosis factor-alpha (TNF-α) was found to promote TRIM32 expression in a time-dependent manner. Furthermore, we observed that overexpression of TRIM32 aggravated the production of pro-inflammatory cytokines in FLS, silencing of TRIM32 showed the consistent results. In addition, TRIM32 was found to activate nuclear factor κB (NF-κB) signalling pathway, and TRIM32 could interact with TNF receptor-associated factor 2 (TRAF2) to promote the K63-linked polyubiquitination of TRAF2 in RA-FLS. In conclusion, we suggested that TRIM32 as a positive regulator of inflammatory responses in RA-FLS.
© 2020 The Scandinavian Foundation for Immunology.

Entities:  

Keywords:  NF-κB; TRAF2; TRIM32; rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32145086     DOI: 10.1111/sji.12876

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  1 in total

1.  Notoginsenoside R1 (NG-R1) Promoted Lymphatic Drainage Function to Ameliorating Rheumatoid Arthritis in TNF-Tg Mice by Suppressing NF-κB Signaling Pathway.

Authors:  Danli Jiao; Yang Liu; Tong Hou; Hao Xu; Xiaoyun Wang; Qi Shi; Yongjun Wang; Qiujuan Xing; Qianqian Liang
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.